ArticleNeurology and therapy2026
Digital Monitoring of Patients with Generalized Myasthenia Gravis: A Prospective Pilot Study.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMonitoring patients with myasthenia gravis (MG) can be challenging due to the fluctuating nature of the disease. We aimed to test the reliability of using the MG Activities of Daily Living (MG-ADL) scale in the form of a smartphone application as a means for optimal patient monitoring and early exacerbation detection.
methodsWe conducted an observational, prospective, single-center study including patients with generalized MG at risk of clinical worsening. Follow-up was based on routine outpatient visits, remote monitoring via weekly self-completion of the MG-ADL scale, and home visits by specialist nurses.
resultsThirty-one patients were included [41.9% female; mean (SD) age 59 (15) years], 87.1% seropositive for anti-AChR antibodies. MG-ADL scores reported by the patient via the application showed excellent agreement with healthcare provider scores (ICC = 0.92, P < 0.01), moderate correlation with the MG Composite scale (ρ = 0.595, P < 0.01), and weak correlation with the Quantitative MG scale (ρ = 0.328, P < 0.01). Over the 15-month follow-up period, compared to 23 exacerbations detected during routine outpatient visits, the application detected 38 exacerbations in 14 patients, 20 of which led to therapeutic modifications.
conclusionThis study demonstrates the reliability of MG-ADL scale data obtained via a smartphone application in reflecting clinical status and in detecting deterioration episodes sometimes missed during routine outpatient visits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.